The REDUCE-IT trial reveals that Vascepa reduced the risk of death due to cardiovascular causes, heart attack, and stroke in patients still at increased cardiovascular risk despite taking statin therapy.
Resources
https://www.eurekalert.org/pub_releases/2018-11/bawh-rrh111018.php
https://www.vascepa.com/
https://www.eurekalert.org/pub_releases/2019-03/bawh-ied031519.php